Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the FirmBusiness Wire • Tuesday
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology WorkshopGlobeNewsWire • 09/09/24
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders SummitGlobeNewsWire • 09/05/24
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyGlobeNewsWire • 08/28/24
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa IndicationGlobeNewsWire • 08/26/24
Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider TradingPRNewsWire • 08/20/24
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis PigmentosaGlobeNewsWire • 08/05/24
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common StockGlobeNewsWire • 08/02/24
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common StockGlobeNewsWire • 08/01/24
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial ResultsGlobeNewsWire • 07/29/24
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene TherapyGlobeNewsWire • 07/25/24
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt DiseaseGlobeNewsWire • 06/21/24
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa IndicationGlobeNewsWire • 06/20/24
OCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGNGlobeNewsWire • 06/10/24
OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGNBusiness Wire • 06/10/24